QNRX

Quoin Pharmaceuticals. Ltd Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website quoinpharma.com
Employees(FY) 4
ISIN US74907L3006

Performance

+0.9%

-26.4%

+25.12%

-17.68%

-87.25%

YTD

-85.78%

Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn, Virginia.

Advanced Technical Analysis

Technical Analysis of QNRX 2024-11-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 16 indicating strong downward pressure, the Oscillators Score at 46 suggesting a neutral stance, and the Technical Score at 31 reinforcing the bearish outlook. This combination implies a cautious market environment, with potential challenges ahead for upwa...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of QNRX

Stock Rank

Recent News & Updates

2024-11-06 19:00
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results(Globenewswire)
2024-11-04 19:00
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient(Globenewswire)
2024-10-31 04:05
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024(Globenewswire)
2024-10-21 20:00
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome(Globenewswire)
2024-09-08 20:30
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO(Globenewswire)
2024-08-07 20:30
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results(Globenewswire)
2024-08-05 17:00
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome(Globenewswire)
2024-08-01 04:10
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024(Globenewswire)
2024-06-26 20:00
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome(Globenewswire)
2024-06-25 04:05
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference(Globenewswire)
2024-06-11 20:00
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland(Globenewswire)
2024-05-08 20:30
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results(Globenewswire)
2024-05-02 04:10
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024(Globenewswire)
2024-03-14 22:52
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-13 04:05
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results(Globenewswire)
2024-03-07 03:05
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET(Globenewswire)
2024-03-04 19:34
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?(Investorplace)
2024-03-04 19:00
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering(Globenewswire)
2024-03-03 19:00
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies(Globenewswire)
2024-02-13 20:00
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome(Accesswire)
2024-02-07 19:00
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product(Globenewswire)
2023-12-12 19:30
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome(Globenewswire)
2023-11-09 23:19
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcript(Yahoo Finance)
2023-11-08 04:46
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results(Globenewswire)
2023-11-02 20:41
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET(Globenewswire)
2023-10-23 21:32
REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome(Globenewswire)
2023-10-23 20:28
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome(Globenewswire)
2023-10-02 00:25
QNRX: Positive Early Clinical Data, Moving QRX003 Through Multiple Trials(Yahoo Finance)
2023-08-08 20:30
Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders(Yahoo Finance)
2023-08-02 04:45
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results(Yahoo Finance)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.